These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16614540)

  • 21. Drugs and valvular heart disease.
    Roth BL
    N Engl J Med; 2007 Jan; 356(1):6-9. PubMed ID: 17202450
    [No Abstract]   [Full Text] [Related]  

  • 22. Dopamine agonists and valvular heart disease.
    Kast RE; Altschuler EL
    N Engl J Med; 2007 Apr; 356(16):1677; author reply 1678-80. PubMed ID: 17447278
    [No Abstract]   [Full Text] [Related]  

  • 23. Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease.
    Reichmann H; Bilsing A; Ehret R; Greulich W; Schulz JB; Schwartz A; Rascol O
    J Neurol; 2006 Aug; 253 Suppl 4():IV36-8. PubMed ID: 16944356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
    Corvol JC; Schüpbach M; Bonnet AM;
    Rev Neurol (Paris); 2005 Jul; 161(6-7):637-43. PubMed ID: 16141947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor-binding and pharmacokinetic properties of dopaminergic agonists.
    Kvernmo T; Houben J; Sylte I
    Curr Top Med Chem; 2008; 8(12):1049-67. PubMed ID: 18691132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ergotamine and nicergoline - facts and myths.
    Zajdel P; Bednarski M; Sapa J; Nowak G
    Pharmacol Rep; 2015 Apr; 67(2):360-3. PubMed ID: 25712664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
    Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.
    Dhawan V; Medcalf P; Stegie F; Jackson G; Basu S; Luce P; Odin P; Chaudhuri KR
    J Neural Transm (Vienna); 2005 May; 112(5):661-8. PubMed ID: 15785862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
    Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
    Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine agonists and valvular heart disease.
    Cheung D; Heaney A
    Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study.
    Droogmans S; Roosens B; Cosyns B; Degaillier C; Hernot S; Weytjens C; Garbar C; Caveliers V; Pipeleers-Marichal M; Franken PR; Lahoutte T; Schoors D; Van Camp G
    Am J Physiol Heart Circ Physiol; 2009 Jun; 296(6):H1940-8. PubMed ID: 19346455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
    Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
    Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
    Valassi E; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
    Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
    Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanobiology of drug-induced cardiac valve disease.
    Lam NT; Balachandran K
    J Long Term Eff Med Implants; 2015; 25(1-2):27-40. PubMed ID: 25955005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 39. 5-HT
    Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V
    Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pergolide-associated valvular heart disease.
    Waller EA; Kaplan J
    Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.